Agilent Technologies introduced SureSelect Human All-Exon V5 and V5 + UTRs for next-generation sequencing. The new all-exon solutions incorporate the latest advances from Agilent Genomics, the ...
Tempus said that the RNA-based xR IVD assay will be offered as a life sciences tool to support drug development programs.
The non-coding genome, once dismissed as "junk DNA", is now recognized as a fundamental regulator of gene expression and a key player in understanding complex diseases. Following the landmark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback